EcoDrugPlus

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSODEG00000011806
Gene Symbol: PSMB4
2 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSODEG00000001779
Gene Symbol: PSMB5
3 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSODEG00000004257
Gene Symbol: PSMB7
2 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSODEG00000017662
Gene Symbol: PSMB8
3 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSODEG00000017656
Gene Symbol: PSMB9
3 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSODEG00000013158
Gene Symbol: PSMD2
3 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSODEG00000007135
Gene Symbol: PSMC2
2 Cross references
221 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSODEG00000016550
Gene Symbol: PSMC3
2 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSODEG00000001476
Gene Symbol: PSMC4
3 Cross references
197 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSODEG00000008510
Gene Symbol: PSMC5
2 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSODEG00000010581
Gene Symbol: PSMC6
2 Cross references
153 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 11

Ensembl ID : ENSODEG00000013615
Gene Symbol: PSMD11
2 Cross references
281 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).